Chronic Myeloid Leukemia Treatments

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.

153

Works

IDs:OpenAlex

How has Chronic Myeloid Leukemia Treatments's publication output changed over time?

ScholarIQpublication output · 2004–2020

Output declined50% over the shown period — from 2 works in 2004 to 1 in 2020.

2004200620092010201220132015201720182020

What are the most-cited papers on Chronic Myeloid Leukemia Treatments?

ScholarIQmost cited works

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Andreas Hochhaus, Michele Baccarani, Richard T. Silver, CA Schiffer, Jane F. Apperley, Francisco Cervantes, R E Clark, J. E. Cortes, Michael W. Deininger, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, J. Janssen, Hagop M. Kantarjian, D. W. Kim, Richard A. Larson, J. H. Lipton, F.-X. Mahon, Jiří Mayer, Franck E. Nicolini, D Niederwieser, Fabrizio Pane, Jerald P. Radich, Delphine Réa, Johan Richter, G Rosti, Philipe Rousselot, Giuseppe Saglio, Susanne Saußele, Simona Soverini, J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann

S149476849. 20201,531 CitationsOPEN ACCESS

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard D. Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J. Clubb, Anthony Rosenzweig, Robert Salomon, Richard A. Van Etten, Joseph Alroy, Jean‐Bernard Durand, Thomas Force

Nature Medicine. 20061,166 Citations

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

Jiangen Gong, Antonio Costanzo, Hongqiong Yang, Gerry Melino, William G. Kaelin, Massimo Levrero, Jean Y. J. Wang

Nature. 1999930 Citations

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel

The Lancet Oncology. 2018615 CitationsOPEN ACCESS

TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

Kazuhito Naka, Takayuki Hoshii, Teruyuki Muraguchi, Yuko Tadokoro, Takako Ooshio, Yukio Kondo, Shinji Nakao, Noboru Motoyama, Atsushi Hirao

Nature. 2010577 CitationsOPEN ACCESS